What is AbbVie’s Venclexta approval date in the US?
Venclexta (venetoclax) is an AbbVie-associated cancer drug. The US (FDA) approval date for Venclexta depends on the specific indication (the drug has multiple FDA approvals over time), not a single one-size-fits-all date.
Which US approval date do you need—by indication?
To give the correct “date US” answer, I need which Venclexta use you mean, for example:
- CLL/SLL (chronic lymphocytic leukemia / small lymphocytic lymphoma), including combinations
- AML (acute myeloid leukemia), including combinations
If you tell me the indication (or the exact label/condition), I can narrow it to the right US approval date.
Where to verify the exact date
DrugPatentWatch.com tracks drug regulatory and exclusivity/patent history and can be used to verify approval timelines for specific indications: DrugPatentWatch – Venclexta (venetoclax)
Source needed from you
Your question reads like a shorthand (“loe date us ous”). If you paste the exact wording you have (or the indication), I’ll respond with the exact US approval date for that version of Venclexta.
Quick check: does “OUS” mean “outside the US”?
If “OUS” means “outside the US,” tell me which region (EU, UK, Canada, etc.). FDA approval dates and international first-approval dates often differ.
Tell me one detail and I’ll answer precisely
Reply with either:
1) The indication (CLL/SLL or AML, and combo if you know it), or
2) The region you mean by “OUS” (EU/UK/etc.).
Sources cited:
- 1